Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution

被引:97
作者
Grimm, Dirk [1 ,2 ,3 ]
Buening, Hildegard [4 ,5 ,6 ,7 ]
机构
[1] Heidelberg Univ Hosp, Dept Infect Dis, Cluster Excellence CellNetworks, Virol, Heidelberg, Germany
[2] Heidelberg Univ, BioQuant Ctr, Heidelberg, Germany
[3] Partner Site Heidelberg, German Ctr Infect Res DZIF, Heidelberg, Germany
[4] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany
[5] Hannover Med Sch, Cluster Excellence REBIRTH, Hannover, Germany
[6] Partner Site Hannover Braunschweig, German Ctr Infect Res DZIF, Hannover, Germany
[7] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany
关键词
AAV; adeno-associated virus; molecular evolution; virus engineering; immune escape; virus-host interaction; ADENOASSOCIATED VIRAL VECTORS; GENE-THERAPY VECTOR; IN-VITRO; VIRUS-INFECTION; TRANSDUCTION; IDENTIFICATION; SELECTION; RECEPTOR; IMPACT; PLASMAPHERESIS;
D O I
10.1089/hum.2017.172
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recombinant gene delivery vectors derived from naturally occurring or genetically engineered adeno-associated viruses (AAV) have taken center stage in human gene therapy, fueled by rapidly accumulating and highly encouraging clinical data. Nonetheless, it has also become evident that the current generation of AAV vectors will require improvements in transduction potency, antibody evasion, and cell specificity in order to realize their full potential and to widen applicability in larger patient cohorts. Fortunately, in the recent past, the field has seen a flurry of exciting new developments that enhance our understanding of AAV vector biology, including virus-host interactions, and/or that expand our arsenal of technologies for AAV capsid design and evolution. This review highlights a collection of latest advances in these areas, which, in the authors' opinion, hold particular promise to propel the AAV vector field forward in the near future, especially when applied in combination. These include fundamental novel insights into the AAV life cycle, from an unexpected role of autophagy and interactions with other viruses to the (re-)discovery of a universal AAV receptor and the function of AAV-AAP for capsid assembly. Concurrently, recent successes in the rational design of next-generation synthetic AAV capsids are pointed out, exemplified by the structure-guided derivation of AAV mutants displaying robust in vivo immune evasion. Finally, a variety of new and innovative strategies for high-throughput generation and screening of AAV capsid libraries are briefly reviewed, including Cre recombinase-based selection, ancestral AAV capsid reconstruction, and DNA barcoding of AAV genomes. All of these examples showcase the present momentum in the AAV field and, together with work by many other academic or industrial entities, raise substantial optimism that the remaining hurdles for human gene therapy with AAV vectors will (soon) be overcome.
引用
收藏
页码:1075 / 1086
页数:12
相关论文
共 77 条
  • [1] Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing
    Adachi, Kei
    Enoki, Tatsuji
    Kawano, Yasuhiro
    Veraz, Michael
    Nakai, Hiroyuki
    [J]. NATURE COMMUNICATIONS, 2014, 5
  • [2] Agbandje-McKenna M, 2011, METHODS MOL BIOL, V807, P47, DOI 10.1007/978-1-61779-370-7_3
  • [3] ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES
    ATCHISON, RW
    CASTO, BC
    HAMMON, WM
    [J]. SCIENCE, 1965, 149 (3685) : 754 - &
  • [4] Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity
    Bartel, Melissa
    Schaffer, David
    Buening, Hildegard
    [J]. FRONTIERS IN MICROBIOLOGY, 2011, 2
  • [5] Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
    Bennett, Jean
    Wellman, Jennifer
    Marshall, Kathleen A.
    McCague, Sarah
    Ashtari, Manzar
    DiStefano-Pappas, Julie
    Elci, Okan U.
    Chung, Daniel C.
    Sun, Junwei
    Wright, J. Fraser
    Cross, Dominique R.
    Aravand, Puya
    Cyckowski, Laura L.
    Bennicelli, Jeannette L.
    Mingozzi, Federico
    Auricchio, Alberto
    Pierce, Eric A.
    Ruggiero, Jason
    Leroy, Bart P.
    Simonelli, Francesca
    High, Katherine A.
    Maguire, Albert M.
    [J]. LANCET, 2016, 388 (10045) : 661 - 672
  • [6] AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
    Bennett, Jean
    Ashtari, Manzar
    Wellman, Jennifer
    Marshall, Kathleen A.
    Cyckowski, Laura L.
    Chung, Daniel C.
    McCague, Sarah
    Pierce, Eric A.
    Chen, Yifeng
    Bennicelli, Jeannette L.
    Zhu, Xiaosong
    Ying, Gui-shuang
    Sun, Junwei
    Wright, J. Fraser
    Auricchio, Alberto
    Simonelli, Francesca
    Shindler, Kenneth S.
    Mingozzi, Federico
    High, Katherine A.
    Maguire, Albert M.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)
  • [7] Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?
    Berns, Kenneth I.
    Byrne, Barry J.
    Flotte, Terence R.
    Gao, Guangping
    Hauswirth, William W.
    Herzog, Roland W.
    Muzyczka, Nicholas
    VandenDriessche, Thierry
    Xiao, Xiao
    Zolotukhin, Sergei
    Srivastava, Arun
    [J]. HUMAN GENE THERAPY, 2015, 26 (12) : 779 - 781
  • [8] Chemical Modulation of Endocytic Sorting Augments Adeno-associated Viral Transduction
    Berry, Garrett E.
    Asokan, Aravind
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (02) : 939 - 947
  • [9] Adeno-associated Vector Toxicity-To Be or Not to Be?
    Buening, Hildegard
    Schmidt, Manfred
    [J]. MOLECULAR THERAPY, 2015, 23 (11) : 1673 - 1675
  • [10] HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production
    Cao, M.
    Zhu, H.
    Bandyopadhyay, S.
    You, H.
    Hermonat, P. L.
    [J]. GENE THERAPY, 2012, 19 (04) : 418 - 424